EYPT Q2 2024 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+4.1% YoY

Gross Profit

$8M85.2% margin

Operating Income

-$35M-364.5% margin

Net Income

-$31M-325.3% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

-18.9%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$324M

Total Liabilities

$96M

Stockholders' Equity

$228M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$9M	+4.1%
Gross Profit	$8M	$7M	+10.4%
Operating Income	-$35M	-$23M	-51.8%
Net Income	-$31M	-$23M	-34.5%

Revenue Segments

License And Collaboration Agreement

$8M74%

Y U T I Q Product

$1M10%

Product

$1M10%

Royalty

$627,0006%